Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tecarfarin Anti-Coagulation Trial (TACT) (TACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02522221
Recruitment Status : Not yet recruiting
First Posted : August 13, 2015
Last Update Posted : January 25, 2018
Sponsor:
Information provided by (Responsible Party):
Espero Biopharma

Tracking Information
First Submitted Date  ICMJE August 7, 2015
First Posted Date  ICMJE August 13, 2015
Last Update Posted Date January 25, 2018
Estimated Study Start Date  ICMJE June 1, 2018
Estimated Primary Completion Date March 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 23, 2018)
Percentage of time in the therapeutic range (TTR) for tecarfarin vs. warfarin for each treatment group in the randomized population [ Time Frame: From the date of randomization until study termination, up to 24 months (1st month not included) ]
Interpolated and observed TTR will be calculated for the two treatment groups
Original Primary Outcome Measures  ICMJE
 (submitted: August 12, 2015)
Time in the therapeutic range (TTR) for tecarfarin vs. warfarin in the primary endpoint population [ Time Frame: At least one year after enrollment ]
The primary endpoint is a nested group which is blinded to investigators and subjects. It consists of a subgroup of the overall population which takes at least one drug known to interact with CYP2C9 and who have at least one CYP2C9 variant allele.
Change History Complete list of historical versions of study NCT02522221 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: January 23, 2018)
  • Percentage TTR for tecarfarin vs. warfarin in the sub-population of patients who are taking a CYP2C9-interacting medication and have a CYP2C9 genotype variant allele [ Time Frame: From the date of randomization until study termination, up to 24 months (1st month not included) ]
    Interpolated and observed TTR will be calculated for the two treatment groups
  • Percentage TTR for tecarfarin vs warfarin for the sub-population of patients who are taking a CYP2C9-interacting medication and have chronic kidney disease stage 3 or 4 (eGFR ≥ 15 to <60 mL/min/1.73 m2) [ Time Frame: From the date of randomization until study termination, up to 24 months (1st month not included) ]
    Interpolated and observed TTR will be calculated for the two treatment groups
  • Percentage of patients with INR > 4.0 for tecarfarin vs. warfarin [ Time Frame: From the date of randomization until study termination, up to 24 months (1st month not included) ]
    Percentage of observations of patients with INR > 4.0 will be calculated for the two treatment groups
  • Percentage of patients with INR > 5.0 [ Time Frame: From the date of randomization until study termination, up to 24 months (1st month not included) ]
    Percentage of observations of patients with INR > 5.0 will be calculated for the two treatment groups
  • Time to first embolic event for tecarfarin vs. warfarin [ Time Frame: From the date of randomization until study termination, up to 24 months ]
    Time from enrollment until any embolic event (CVA, pulmonary embolism, peripheral embolism) while enrolled will be calculated for the two groups
Original Secondary Outcome Measures  ICMJE
 (submitted: August 12, 2015)
  • TTR for tecarfarin vs. warfarin for subjects with a mechanical heart valve [ Time Frame: At least one year after enrollment ]
    TTR will be compared in the subgroup of the overall population who have a mechanical heart valve as the indication for chronic anticoagulation.
  • TTR for tecarfarin vs warfarin for subjects who are taking at least one drug know to interact with CYP2C9 [ Time Frame: At least one year after enrollment ]
    TTR will be compared in the subgroup of the overall population who are know to take at least one drug known to interact with CYP2C9
  • Reduction in embolic stroke for tecarfarin vs. warfarin [ Time Frame: At least one year after enrollment. ]
    Embolic stroke incidence during the study will be compared between tecarfarin and warfarin in the overall group
Current Other Pre-specified Outcome Measures
 (submitted: January 23, 2018)
  • The primary safety endpoint of this study is the time to the first BARC category 3-5 bleeding event. [ Time Frame: From the date of randomization until study termination, up to 24 months ]
    BARC category 3-5 bleeding events will be compared for the two treatment groups
  • The secondary safety endpoint of this study is the time to the first BARC category 2-5 bleeding event [ Time Frame: From the date of randomization until study termination, up to 24 months ]
    BARC category 2-5 bleeding events will be compared for the two treatment groups
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Tecarfarin Anti-Coagulation Trial (TACT)
Official Title  ICMJE A "Real-World", Randomized, Open-Label, Study on the Efficacy, Safety, and Tolerability of Tecarfarin (ATI-5923) a Novel Vitamin K Antagonist, Versus Warfarin in Subjects Requiring Chronic Anticoagulation
Brief Summary TACT is a "real world" randomized controlled trial of tecarfarin, a novel vitamin K antagonist, vs. warfarin. The quality of anticoagulation control will be compared for the two groups of subjects who require chronic oral anticoagulation for a broad panel of indications.
Detailed Description This will be a randomized, parallel-arm, open-label study comparing the safety and efficacy of tecarfarin and warfarin in approximately 1000 subjects who have an indication for chronic oral anticoagulation. The study will be fully enriched with subjects who are taking at least one CYP2C9-interacting medication and have either chronic kidney disease stage 3 or 4 and/or a genetic variant allele for CYP2C9. The study will be conducted at approximately 140 sites with experience in the management of anticoagulation subjects. Eligible subjects will be randomized to receive either tecarfarin or warfarin for a period ranging from 6 months to a maximum of approximately 24 months.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Thromboembolism
  • Thrombosis
Intervention  ICMJE
  • Drug: Warfarin
    Warfarin is an oral vitamin K antagonist anticoagulant.
    Other Name: Coumadin
  • Drug: tecarfarin
    Tecarfarin is an oral vitamin K antagonist anticoagulant
    Other Name: ATI-5923
Study Arms  ICMJE
  • Experimental: Tecarfarin
    Tecarfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
    Intervention: Drug: tecarfarin
  • Active Comparator: Warfarin
    Warfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
    Intervention: Drug: Warfarin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: January 23, 2018)
1000
Original Estimated Enrollment  ICMJE
 (submitted: August 12, 2015)
3000
Estimated Study Completion Date  ICMJE July 1, 2019
Estimated Primary Completion Date March 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

General Screening Inclusion Criteria

  1. Is male or female and at least 18 years of age.
  2. Is able and willing to sign an IRB-approved written informed consent.
  3. Is able and willing to follow instructions, to comply with protocol requirements, and to attend required study visits.
  4. Is taking a CYP2C9-interacting medication (inhibitor, substrate, or inducer; see list in Appendix A) at the time of randomization and is expected to receive this medication chronically for the duration of the trial.
  5. Has either

    1. Chronic kidney disease stage 3 or 4 (eGFR ≥ 15 to <60 mL/min/1.73 m2 at Screening based on central laboratory) and/or
    2. A CYP2C9 genotype variant allele
  6. (Only for warfarin experienced patients) Patient is considered poorly controlled on warfarin therapy as judged by the investigator, e.g. has at least 2 INR values out of target range within previous 12 months Anticoagulation-Related Inclusion Criteria
  7. Requires chronic anticoagulation therapy.
  8. Is willing to receive chronic anticoagulation investigational therapy for the duration of the study or, for warfarin-naïve DVT subjects, treating physician prescribed at least a 6-month treatment period with an oral anticoagulation agent.
  9. Has one or more of the following indications for chronic oral anticoagulation:

    1. Atrial fibrillation/flutter (paroxysmal, persistent or permanent), not due to a reversible cause, documented by electrocardiography (ECG)
    2. Aortic and/or mitral prosthetic HV
    3. History of venous thromboembolic disease
    4. History of myocardial infarction or cardiomyopathy
    5. Any another indication for which warfarin is approved or recommended, with Sponsor approval
  10. Conforms to the following restrictions regarding vitamin-K containing dietary supplements:

    1. If taking at Baseline (Visit 2), is willing to continue with consistent doses throughout the study
    2. If not taking at Baseline (Visit 2), is willing to abstain from such supplements throughout the study

General Exclusion Criteria

  1. Is pregnant, nursing, or a woman of childbearing potential who cannot assure that they will not become pregnant for the duration of the study.
  2. Has been treated with an investigational drug within 30 days or 5 half-lives, whichever is longer, at time of screening.

    Safety-Related Exclusion Criteria

  3. Has a life expectancy <1 year
  4. Is age >85 years
  5. Has severe end-organ disease, such as:

    1. Estimated GFR (eGFR) < 15 mL/min/1.73 m2 at Screening per the central laboratory
    2. Is on dialysis
    3. Is expected to be on dialysis or receive kidney transplant within 6 months of screening
    4. Advanced pulmonary disease requiring home oxygen
    5. NYHA class IV heart failure
    6. Severe psychiatric disorder such as advanced dementia
  6. Has a history of ischemic stroke without residual neurologic deficit within the last 3 months, prior major ischemic stroke with residual neurologic deficit, or any history of intracranial bleeding
  7. Is an ongoing alcohol or substance abuser
  8. Has anemia (screening hemoglobin <9 g/dL) For subjects who have received a MHV within 4 weeks of Screening, who have no active bleeding, and whose hemoglobin is stable, a Screening hemoglobin as low as 8 g/dL is allowed.

    For subjects with severe CKD (eGFR ≥ 15 to <30 mL/min/1.73 m2), who have no active bleeding, and whose hemoglobin is stable, a Screening hemoglobin as low as 8 g/dL is allowed.

  9. Has thrombocytopenia (screening platelet count <90,000 x 103/microL)
  10. Has a history of or presence of any illness or condition, which, in the judgment of the Investigator, may compromise the safety of the subject during Study Drug administration.

    Anticoagulation-related Exclusion Criteria

  11. Has active bleeding or lesions at risk of bleeding such as gastric ulceration, colonic or cerebral arterio-venous malformations, cerebral or aortic aneurysms, pericarditis or endocarditis
  12. Except for MHV replacement surgery and related or concurrent procedures, has recently (<14 days from Screening) undergone non-thromboembolic surgery or other invasive procedures such as lumbar puncture.
  13. Has blood dyscrasias or inherited disorders of hemostasis.
  14. Has a history of hemorrhagic tendencies or prior serious hemorrhagic events such as hemorrhage within the cranium, eye, spinal cord, retroperitoneum.
  15. Has active gross hematuria or gastrointestinal bleeding
  16. Has a history of gross hematuria or gastrointestinal bleeding within the past 6 months prior to Screening. (Note: Investigators may enroll patients with such bleeding episodes if they are resolved at least 4 weeks prior to screening and if the benefits of anticoagulation outweigh the risks using accepted risk stratification methods such as HASBLED.)
  17. Has received concomitant therapy with other anticoagulant or antiplatelet agents, such as clopidogrel, prasugrel, ticlopidine, dipyridamole, heparin or low molecular weight heparin (LMWH), or nonsteroidal anti-inflammatory drugs (NSAIDs) that cannot be discontinued prior to initiating tecarfarin/warfarin dosing, unless use of such drugs is necessary as part of bridging/transitioning during the first several days of Study Drug administration.

    Daily use of 81 - 100 mg aspirin and intermittent or chronic use of the selective COX-2 inhibitors celecoxib and valdecoxib is allowed.

  18. Has congenital or acquired coagulant inhibitors present which would interfere with the use of the INR, eg:

    1. Antiphospholipid antibody syndrome or positive lupus anticoagulant
    2. Abnormally prolonged prothrombin time, in the absence of therapeutic anticoagulation, due to an endogenous inhibitor
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02522221
Other Study ID Numbers  ICMJE CLN-511
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Espero Biopharma
Study Sponsor  ICMJE Espero Biopharma
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Espero Biopharma
Verification Date January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP